Is Afamin a novel biomarker for gestational diabetes mellitus? A pilot study.
Angela KöningerAnnette MathanPawel MachMirjam FrankBoerge SchmidtEkkehard SchleussnerRainer KimmigAlexandra GellhausHans DieplingerPublished in: Reproductive biology and endocrinology : RB&E (2018)
Afamin may serve as a new early biomarker for pathological glucose metabolism during pregnancy. Further research is needed to determine afamin's concentrations during pregnancy, its predictive value for early detection of pregnancies at high risk to develop GDM and its diagnostic role during the second trimester.